GIC and Advent International to Takeover Swedish Orphan Biovitrum
Posted on 09/02/2021
Swedish Orphan Biovitrum AB (publ) (SOBI), a listed company, is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden. Advent International and Singapore’s GIC Private Limited made an 69.4 billion SEK (US$ 8 billion) takeover offer for SOBI. SOBI said its board had unanimously recommended that shareholders accept the offer from Advent and Aurora, which is a nominated investment vehicle of GIC Special Investments Pte Ltd.
Investor AB (Investor Aktiebolag) has around a 36.45% in SOBI. Fjärde AP-Fonden (AP4) has a 6.96% stake in SOBI. Both of these shareholders agreed to the offer.
Agnafit Bidco AB, a Swedish limited liability company, is the bidco of the buyers.
J.P. Morgan Securities Plc and Evercore Partners International LLP are financial advisors to Agnafit Bidco in connection with the Offer.
Roschier Advokatbyrå AB and Weil, Gotshal & Manges (London) LLP are legal advisors to Agnafit Bidco and Advent, and Linklaters LLP are legal advisers to Aurora, in connection with the Offer.